TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer ...

In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target of £114.00. The company’s shares opened today at ...

(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...

Converting images into vector graphics or creating vector graphics is particularly useful if you need graphics for logos, illustrations, or print templates. While conventional image formats such ...

NEW YORK – AstraZeneca and Daiichi Sankyo's filing last week seeking approval for Enhertu (trastuzumab deruxtecan) in HER2-low and -ultralow hormone receptor (HR)-positive advanced breast cancer ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs ...

AstraZeneca has today officially opened The Hub in Cambridge, a purposely designed amenities centre, where employees and the local community can collaborate, socialise and unwind. Located at the heart ...

The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.

The 2024 AstraZeneca prize in synthetic chemistry has been awarded to Ruth Webster, University of Cambridge, for her productive early career and innovative research, particularly in iron catalysis, ...